Onsenal

RSS
Withdrawn

This medicine's authorisation has been withdrawn

celecoxib
MedicineHumanWithdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 17 October 2003 the European Commission issued a marketing authorisation under exceptional circumstances valid throughout the European Union for the medicinal product Onsenal (celecoxib) for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis, as an adjunct to surgery and further endoscopic surveillance. 

A marketing authorisation under exceptional circumstances may be granted if the applicant is unable to provide comprehensive data on the efficacy and safety of the medicine for which authorisation is being sought, due to the rarity of the condition it is intended for, limited scientific knowledge in the area concerned, or ethical considerations involved in the collection of such data. Therefore, it will normally be subject to specific obligation(s) during its life-cycle. 

At the time of marketing authorisation for Onsenal, the applicant was given a specific obligation to provide further data on its efficacy and safety. The marketing authorisation holder (MAH) for Onsenal was Pfizer Limited. The European Commission was notified by a letter dated 10 March 2011 of the MAH’s decision to voluntarily withdraw the marketing authorisation for Onsenal. 

The reason given was that the MAH has not yet been able to provide the additional data required to fulfil its specific obligation, as a result of slow enrolment in an ongoing clinical trial. Onsenal was marketed in all EU countries except for Bulgaria, Hungary, Malta, Romania and Slovenia. At the time of the withdrawal, Onsenal was undergoing the 8th annual reassessment by the CHMP. 

On the basis of the documentation submitted, the CHMP was of the view that the specific obligation necessary to maintain the marketing authorisation had not been fulfilled. The CHMP, therefore, requested supplementary information to be provided in order to confirm that the benefits associated with the use of Onsenal in the treatment of familial adenomatous polyposis still outweigh its risks.

On 28 March 2011 the European Commission issued a decision to withdraw the marketing authorisation for Onsenal.

Pursuant to this decision the European Public Assessment Report for Onsenal is updated to reflect that the marketing authorisation is no longer valid.

български (BG) (413.76 KB - PDF)

View

español (ES) (330.59 KB - PDF)

View

čeština (CS) (382.99 KB - PDF)

View

dansk (DA) (329.69 KB - PDF)

View

Deutsch (DE) (330.69 KB - PDF)

View

eesti keel (ET) (328.93 KB - PDF)

View

ελληνικά (EL) (419.21 KB - PDF)

View

français (FR) (330.54 KB - PDF)

View

italiano (IT) (330.09 KB - PDF)

View

latviešu valoda (LV) (387.05 KB - PDF)

View

lietuvių kalba (LT) (355.07 KB - PDF)

View

magyar (HU) (378.98 KB - PDF)

View

Malti (MT) (398.93 KB - PDF)

View

Nederlands (NL) (328.95 KB - PDF)

View

polski (PL) (384.61 KB - PDF)

View

português (PT) (330 KB - PDF)

View

română (RO) (354.09 KB - PDF)

View

slovenčina (SK) (382.91 KB - PDF)

View

slovenščina (SL) (378.8 KB - PDF)

View

Suomi (FI) (329.99 KB - PDF)

View

svenska (SV) (329.33 KB - PDF)

View

Product information

български (BG) (1.75 MB - PDF)

View

español (ES) (808.39 KB - PDF)

View

čeština (CS) (1.27 MB - PDF)

View

dansk (DA) (787.42 KB - PDF)

View

Deutsch (DE) (828.55 KB - PDF)

View

eesti keel (ET) (791.7 KB - PDF)

View

ελληνικά (EL) (1.87 MB - PDF)

View

français (FR) (850.82 KB - PDF)

View

íslenska (IS) (800.8 KB - PDF)

View

italiano (IT) (811.86 KB - PDF)

View

latviešu valoda (LV) (1.35 MB - PDF)

View

lietuvių kalba (LT) (810.35 KB - PDF)

View

magyar (HU) (1.39 MB - PDF)

View

Malti (MT) (1.46 MB - PDF)

View

Nederlands (NL) (803.39 KB - PDF)

View

norsk (NO) (778.55 KB - PDF)

View

polski (PL) (1.44 MB - PDF)

View

português (PT) (827.81 KB - PDF)

View

română (RO) (821.02 KB - PDF)

View

slovenčina (SK) (1.4 MB - PDF)

View

slovenščina (SL) (1.27 MB - PDF)

View

Suomi (FI) (802.87 KB - PDF)

View

svenska (SV) (767.89 KB - PDF)

View
Latest procedure affecting product information: II/0028
28/03/2011
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Product details

Name of medicine
Onsenal
Active substance
Celecoxib
International non-proprietary name (INN) or common name
celecoxib
Therapeutic area (MeSH)
Adenomatous Polyposis Coli
Anatomical therapeutic chemical (ATC) code
L01XX33

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Onsenal is indicated for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance (see section 4.4).

The effect of Onsenal-induced reduction of polyp burden on the risk of intestinal cancer has not been demonstrated (see sections 4.4 and 5.1)

Authorisation details

EMA product number
EMEA/H/C/000466

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see Pre-authorisation guidance.

Marketing authorisation holder
Pfizer Limited

Ramsgate Road
Sandwich
Kent
CT13 9NJ
United Kingdom

Marketing authorisation issued
17/10/2003
Withdrawal of marketing authorisation
28/11/2008
Revision
13

Assessment history

español (ES) (298.99 KB - PDF)

View

čeština (CS) (342.77 KB - PDF)

View

dansk (DA) (303.87 KB - PDF)

View

Deutsch (DE) (306.78 KB - PDF)

View

eesti keel (ET) (297.18 KB - PDF)

View

ελληνικά (EL) (382.68 KB - PDF)

View

français (FR) (303.88 KB - PDF)

View

italiano (IT) (296.88 KB - PDF)

View

latviešu valoda (LV) (363.8 KB - PDF)

View

lietuvių kalba (LT) (334.44 KB - PDF)

View

magyar (HU) (342.38 KB - PDF)

View

Nederlands (NL) (301.31 KB - PDF)

View

polski (PL) (356.38 KB - PDF)

View

português (PT) (305.83 KB - PDF)

View

slovenčina (SK) (343.33 KB - PDF)

View

slovenščina (SL) (342.21 KB - PDF)

View

Suomi (FI) (300.62 KB - PDF)

View

svenska (SV) (300.06 KB - PDF)

View

This page was last updated on

Share this page